A Penny Saved: Why Delaying 340B Pricing Rule Is Good News For Companies Like Horizon

HRSA proposes another delay to effective date of final rule on calculating the ceiling prices for drugs sold to 340B program. Agency also appears ready to reconsider the 'penny pricing' policy that rule would codify.

US pennies

At 11:15 am on Aug. 17, the Health Resources & Services Administration released an advanced copy of a Federal Register notice proposing another delay in its final rule on calculating 340B drug prices (and imposing civil money penalties for manufacturers who violate those rules).

By noon, shares of Horizon Pharma PLC were up

More from Market Access

More from Pink Sheet